paclitaxel-coated balloon

Clinical Trial Update

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

12/09/2019

William A. Gray, MD, FACC, FSCAI

System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania

William A. Gray, MD, FACC, FSCAI ...

Vascular Disease Management talks with IMPERIAL trial co-principal investigator William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania.

Vascular Disease Management...

12/09/2019

Vascular Disease Management

Rapid Communication

Lower Paclitaxel Dose, Smaller Delivery Platform: 12-Month Data From the RANGER SFA II Trial

11/12/2019

Ravish Sachar, MD, FACC

University of North Carolina Rex Hospital Physician-in-Chief for Heart and Vascular Services

Ravish Sachar, MD, FACC Universit...

Vascular Disease Management talks with Ravish Sachar, MD, FACC, University of North Carolina - Rex Hospital Physician-in-Chief for Heart and Vascular Services, and Principal Investigator of the RANGER II SFA trial.

Vascular Disease Management...

11/12/2019

Vascular Disease Management

EP Tips & Techniques

Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial

07/23/2019

Jihad A. Mustapha, MD¹; Marianne Brodmann, MD²; Patrick J. Geraghty, MD³; Fadi Saab, MD¹; Richard A. Settlage, MS⁴; Michael R. Jaff, DO⁵; on behalf of the Lutonix BTK Study Investigators

Jihad A. Mustapha, MD1; Marianne Bro...

We hypothesized that a drug-coated balloon could improve treatment efficacy while maintaining safety when compared with percutaneous transluminal angioplasty for the treatment of atherosclerotic infrapopliteal arterial lesions.

We hypothesized that a...

07/23/2019

Journal of Invasive Cardiology

FDA Panel

Current Antiproliferative Considerations: The Eluvia Stent

06/25/2019

Steve Henao, MD, FACS, FACC

Vascular Surgery and Vascular Interventional Radiology, New Mexico Heart Institute, Albuquerque, New Mexico

Steve Henao, MD, FACS, FACC Vascu...

Steve Henao, MD, FACS, FACC, from New Mexico Heart Institute, Albuquerque, New Mexico, discusses the use of paclitaxel-coated devices to treat PAD.

Steve Henao, MD, FACS, FACC,...

06/25/2019

Vascular Disease Management

FDA Panel

Accepting the Risk of Treatment with Drug-Coated Balloons

06/22/2019

Frank J. Veith, MD

Professor of Surgery, New York University-Langone Medical Center and The Cleveland Clinic Lerner College of Medicine; The William J. von Liebig Chair in Vascular Surgery; Cleveland, Ohio and New York, New York; Founder and Chairman of VEITHsymposium

Frank J. Veith, MD Professor of S...

VDM talks with Frank J. Veith, MD, Professor of Surgery, New York University-Langone Medical Center and The Cleveland Clinic Lerner College of Medicine; The William J. von Liebig Chair in Vascular Surgery; Cleveland, Ohio and New York, New...

VDM talks with Frank J. Veith,...

06/22/2019

Vascular Disease Management

Editor's Corner

A Potential Danger Signal Associated With Paclitaxel-Eluting Devices

01/21/2019

Craig Walker, MD

Cardiovascular Institute of the South, Houma, Louisiana

Craig Walker, MD Cardiovascular I...

Dr. Walker comments on a hotly debated meta-analysis by Katsanos and colleagues on the risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg.

Dr. Walker comments on a hotly...

01/21/2019

Vascular Disease Management

Original Contribution

Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease

06/30/2016

Sanjum S. Sethi, MD, MPH and Michael S. Lee, MD

Sanjum S. Sethi, MD, MPH and Michael ...

A review of paclitaxel-coated balloons as an emerging therapeutic option for the invasive management of infrainguinal peripheral artery disease.

A review of paclitaxel-coated...

06/30/2016

Journal of Invasive Cardiology